Join to View Full Profile
Dana-Farber Cancer Institute450 Brookline AveBoston, MA 02215
Phone+1 617-632-3800
Fax+1 617-632-1930
Dr. Partridge is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Mass General Brigham/Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 1998 - 2001
University of Pennsylvania Health SystemResidency, Internal Medicine, 1995 - 1998
Weill Cornell MedicineClass of 1995
Certifications & Licensure
MA State Medical License 1998 - 2026
PA State Medical License 1996 - 1998
American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Regional Top Doctor Castle Connolly, 2014
- Super Doctor SuperDoctors.com
Clinical Trials
- S0230 Goserelin in Preventing Ovarian Failure in Women Receiving Chemotherapy for Breast Cancer Start of enrollment: 2003 Oct 01
- Extended Endocrine Therapy for Premenopausal Women With Breast Cancer Start of enrollment: 2009 May 01
- The Young Women's Breast Cancer Study Start of enrollment: 2006 Nov 01
- Join now to see all
Publications & Presentations
PubMed
- 1 citationsAdjuvant Dose-Dense Chemotherapy in Hormone Receptor-Positive Breast Cancer.Otto Metzger Filho, Karla Ballman, Jordan Campbell, Minetta Liu, Jennifer Ligibel
Journal of Clinical Oncology. 2025-04-01 - Impact of adding palbociclib on treatment adherence to ongoing adjuvant endocrine treatment in the global randomized PALLAS randomized trial in patients with early bre...Eileen Shinn, David Zahrieh, Angela DeMichele, Nick Zdenkowski, Julie Lemieux
Breast Cancer Research and Treatment. 2025-03-27 - Fertility Preservation in People With Cancer: ASCO Guideline Update.H Irene Su, Christina Lacchetti, Joseph Letourneau, Ann H Partridge, Rubina Qamar
Journal of Clinical Oncology. 2025-03-19
Journal Articles
- Effect of Sustained Smoking Cessation Counseling and Provision of Medication vs Shorter-Term Counseling and Medication Advice on Smoking Abstinence in Patients Recentl...Jennifer S Temel, Ann H Partridge, JAMA
- Effect of Eribulin with or Without Pembrolizumab on Progression-Free Survival for Patients with Hormone Receptor–Positive, ERBB2-Negative Metastatic Breast CancerSara M Tolaney, Gerburg Wulf, Laura Spring, Beth Overmoyer, Ann H Partridge, Eric P Winer, Ian E Krop, JAMA Oncology
Lectures
- POSITIVE (IBCSG 48-14/BIG 8-13/A221405): Evaluating outcomes after interrupting endocrine therapy (ET) for women with endocrine responsive (ER+) early breast cancer (B...2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
Other
- Approach to the long-term survivor of breast cancerPartridge AH, Ruddy KJ
http://www.uptodate.com/contents/approach-to-the-long-term-survivor-of-breast-cancer
UpToDate, Wolters Kluwer Health - 2013-03-29
Press Mentions
Less Than 50% of Women with Breast Cancer Resume Endocrine Therapy After PregnancyApril 2nd, 2025- How Oncologists Can Help Breast Cancer Survivors Cope with Fear of RecurrenceFebruary 25th, 2025
- She Wanted to Be a Mom. So She Chose a Cancer Treatment That Gave Her a ChanceFebruary 12th, 2025
- Join now to see all
Professional Memberships
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
